Recent

% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

  • rationalthought11 rationalthought11 Dec 27, 2011 11:29 AM Flag

    Stock issuance insures price will remain low

    The Put shares contemplated by the registration statement will be resold by Four M representing a 7mm share overhang of stock. I expect most of the buyers of the 25mm equity raise backstopped by Toucan, and most of the debt holders that converted debt to equity will also be sellers. The debt holders converted because the debt would never have been repaid, but as equity holders they can sell off their positions to retail investors and recoup at least some of their money. In the face of these likely sellers, upward price action will be extremely difficult for the next 18 months or so, and share issuance will be taking place at very low stock prices, which means much more dilution for us retail holders. Les Goldman's happy face notwithstanding , converted debt holders (including Cognate) are probably liquidating some or all of their positions as we speak. No reason to expect higher prices until the results of the trial are announced-- 18-24 months from now. Paradoxically, generally speaking, the later the results are announced, the better for shareholders. Hunker down. Sorry.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NWBO
11.42+0.08(+0.71%)Jul 31 4:00 PMEDT